PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.31%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
-49.44%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
3.87%
Other expenses growth less than half of CRVO's 100.00%. David Dodd would verify if advantage is sustainable.
-37.34%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-37.34%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
-62.14%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
3.87%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
47.24%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
37.34%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
1271.24%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
47.13%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-62.14%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
47.13%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
50.90%
EPS growth while CRVO declines. John Neff would investigate advantages.
52.86%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
7.67%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
12.32%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.